Menarini Tenkasi Receives EU Approval and Expands Indication to Include Pediatric Use, Strengthening its Position in the Single-Dose Market
Not a New Approval, but a Commercialized Antibiotic
Tenkasi is a semi-synthetic lipoglycopeptide antibiotic with oritavancin diphosphate as its active ingredient. The EU marketing authorization was initially granted on March 19, 2015, under the name Orbactiv, and the product name was changed to Tenkasi on August 9, 2021. Therefore, the current EMA page should be interpreted as a compilation of accumulated regulatory information for a marketed product, rather than a new approval announcement. The current marketing authorization holder is Menarini International Operations Luxembourg, a non-listed pharmaceutical company, and the clinical stage is Marketed.
Three Mechanisms of Action and the Advantage of Single-Dose Intravenous Administration
Oritavancin binds to the peptidoglycan precursor and the cell wall cross-linking region, inhibiting transglycosylation and transpeptidation, and also damages the bacterial membrane, exhibiting three mechanisms of action. In adults with acute bacterial skin and skin structure infections (ABSSSI), a single 1,200mg intravenous dose constitutes the entire treatment course, differentiating it from vancomycin, which requires repeated administrations. The two confirmatory Phase 3 SOLO I and II trials demonstrated non-inferiority compared to vancomycin followed by oral cephalexin, which was the key basis for approval. Single-dose administration is advantageous for outpatient conversion and bed turnover, but it is also important to manage the fact that it is difficult to immediately reverse adverse reactions after administration due to its long half-life.
Pediatric Expansion and a Challenging Regulatory History
The current EMA indication is for the treatment of ABSSSI in adults and children 3 months of age and older. A study of 38 children showed that, when administered at the recommended dose, drug exposure was similar to that in adults. This reflects the inclusion of pediatric use in the 2023 marketing authorization amendment, which represents an expansion of the product lifecycle rather than a new drug approval. The regulatory pathway was not without challenges; in 2008, the US FDA Advisory Committee determined by a vote of 10 to 8 that the safety and efficacy were not demonstrated based on the data at the time, and the FDA issued a Complete Response Letter. Subsequently, new single-dose Phase 3 data were submitted, and the FDA approved Orbactiv on August 6, 2014, and the EMA CHMP adopted a positive opinion on January 22, 2015.
Competitive Landscape and Rights Structure
Generic vancomycin, teicoplanin, and long-acting competitors such as AbbVie's Xydalba (dalbavancin), Menarini's Quofenix (delafloxacin), and Pfizer's Zyvox (linezolid) compete in the same ABSSSI market. The global ABSSSI treatment market is projected to expand from approximately USD 3.16 billion in 2025 to USD 3.42 billion in 2026, but antibiotic stewardship and low-cost generics limit the expansion of premium pricing. In 2018, Menarini secured a co-development and exclusive sales agreement for 68 countries, including Tenkasi, from Melinta Therapeutics, with a total contract value of up to USD 265 million. The agreement includes an upfront payment of EUR 17 million, approval and sales milestones, and royalties linked to net sales, meaning that the commercial performance of Tenkasi in Europe is directly linked to the economics of the rights holder.
From an investor's perspective, Tenkasi is a commercialized asset that has completed Phase 3 clinical trials and received EU and US approvals, so the key factors in its valuation are prescription penetration, country-specific pricing, and antibiotic stewardship, rather than development risk. For researchers, the mechanistic and pharmacokinetic differentiation of targeting two stages of cell wall synthesis and the bacterial membrane simultaneously, and the availability of a single 1,200mg dose, are important, but the accumulated experience with vancomycin and dalbavancin serves as a benchmark. For the industry, the global ABSSSI market of approximately USD 3.16 billion in 2025 and the addition of pediatric use from 3 months of age provide additional demand, while low-cost generics and infection control policies limit sales leverage. In the short term, approval and adoption by European countries are key, and in the medium to long term, the key is whether Menarini can leverage the 68-country sales network secured in the 2018 agreement, with a maximum value of USD 265 million, to demonstrate the cost-effectiveness of outpatient single-dose treatment.
Source: EMA (ema)